Switching From Standard to Extended Half‐Life Coagulation Factor Replacement in Haemophilia: Clinical Outcomes and Costs of Care in Finland
Majority of patients on prophylaxis switched to EHL. The switch alleviated the infusion regimen, tended to lower bleeding rates and improved adherence with somewhat increased costs.
Authors
- Tímea Szántó (ORCID: https://orcid.org/0000-0001-7006-6564)
- Timo Siitonen
- Anna‐Elina Lehtinen
- Johanna Haapkylä
- Mirkka Koivusalo
- Marko Vesanen
- Riitta Lassila (ORCID: https://orcid.org/0000-0002-1911-3094)
- Aino Vesikansa (ORCID: https://orcid.org/0000-0002-6386-9956)
- Anu Partanen (ORCID: https://orcid.org/0000-0002-5634-2582)
- Juha Mehtälä (ORCID: https://orcid.org/0000-0003-4088-8561)
- Outi Laine
- Tuomas Kovalainen
- Nina Sarnesto
Institutions
- University of Helsinki (FI)
- Oulu University Hospital (FI)
- Helsinki University Hospital (FI)
- Turku University Hospital (FI)
- Kuopio University Hospital (FI)
- Novo Nordisk (Finland) (FI)
- Tampere University Hospital (FI)
- Tampere University (FI)
Publication Details
- Journal
- Haemophilia
- Published
- 2025-06-21
- DOI
- https://doi.org/10.1111/hae.70067
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novo Nordisk
- Tays
- Novo Nordisk Pharma